Niklas Kehl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Niklas Kehl has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Marc Steffen Raab
Department of Hematology, Oncology and Rheumatology Heidelberg University Hospital Heidelberg Germany
25 shared publications - Mirco J. Friedrich
German Cancer Research Center (DKFZ), JRG Hematology and Immune Engineering, Heidelberg, Germany
25 shared publications - Carsten Müller-Tidow
University Hospital Heidelberg, Heidelberg, Germany
24 shared publications - Christine Riedhammer
University Hospital of Würzburg 3 Department of Internal Medicine II Würzburg, Germany
24 shared publications - Christoph Schaefers
Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology University Medical Center Hamburg‐Eppendorf Hamburg Germany
24 shared publications - David Sedloev
Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg Heidelberg, Germany
24 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S4.Complications and toxicities – CAR-HEMATOTOX (HTX) < 3 vs. ≥ 3
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S4.Complications and toxicities – CAR-HEMATOTOX (HTX) < 3 vs. ≥ 3
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S8. Cytopenias before and during treatment and associated supportive measures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S8. Cytopenias before and during treatment and associated supportive measures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S7. Multivariable logistic regression analyses: Hospitalization ≥ 14 days
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S7. Multivariable logistic regression analyses: Hospitalization ≥ 14 days
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S3. Complications and toxicities
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S3. Complications and toxicities
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S10. Cytopenias before and during treatment – m-EASIX ≤ median vs. > median
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S10. Cytopenias before and during treatment – m-EASIX ≤ median vs. > median
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S17 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S17. Multivariable Cox regression analyses: Progression-free survival
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S17 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S17. Multivariable Cox regression analyses: Progression-free survival
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S16. Univariable Cox regression analysis: Overall survival
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S16. Univariable Cox regression analysis: Overall survival
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S5. Complications and toxicities – m-EASIX ≤ median vs. > median
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S5. Complications and toxicities – m-EASIX ≤ median vs. > median
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S6. Univariable logistic regression analysis: Hospitalization ≥ 14 days
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S6. Univariable logistic regression analysis: Hospitalization ≥ 14 days
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S12. Multivariable Cox regression analyses: Time to severe infection
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy
Supp. Table S12. Multivariable Cox regression analyses: Time to severe infection